Abstract
Type 2 Diabetes Mellitus (T2D) and osteoporosis have been found recently to be tightly correlated. In fact, T2D can result in bone loss through different mechanisms resulting in alteration of bone matrix and inhibition of bone formation. Fracture risk also increases significantly. New antidiabetic agents, dipeptidyl peptidase-4 inhibitors and glucagon like peptide -1 agonists have shown promise in many fields beyond glycemic control. Benefits on the skeletal system are multiple through direct stimulation of osteoblasts, inhibition of advanced glycation end products and inhibition of bone resorption. However, clinical evidence in humans is still not enough to allow definitive conclusions.
Keywords: Dipeptidyl peptidase-4 inhibitors, glucagon like peptide -1 agonists, incretin therapy, osteoporosis, type 2 diabetes mellitus.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Incretin Based Therapies: Bone Protective Effects
Volume: 13 Issue: 4
Author(s): Marlene Chakhtoura and Sami T. Azar
Affiliation:
Keywords: Dipeptidyl peptidase-4 inhibitors, glucagon like peptide -1 agonists, incretin therapy, osteoporosis, type 2 diabetes mellitus.
Abstract: Type 2 Diabetes Mellitus (T2D) and osteoporosis have been found recently to be tightly correlated. In fact, T2D can result in bone loss through different mechanisms resulting in alteration of bone matrix and inhibition of bone formation. Fracture risk also increases significantly. New antidiabetic agents, dipeptidyl peptidase-4 inhibitors and glucagon like peptide -1 agonists have shown promise in many fields beyond glycemic control. Benefits on the skeletal system are multiple through direct stimulation of osteoblasts, inhibition of advanced glycation end products and inhibition of bone resorption. However, clinical evidence in humans is still not enough to allow definitive conclusions.
Export Options
About this article
Cite this article as:
Chakhtoura Marlene and Azar T. Sami, Incretin Based Therapies: Bone Protective Effects, Endocrine, Metabolic & Immune Disorders - Drug Targets 2013; 13 (4) . https://dx.doi.org/10.2174/18715303113136660046
DOI https://dx.doi.org/10.2174/18715303113136660046 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Teratogenic Potential of Atypical Antipsychotic Drugs, Quetiapine and Aripiprazole in Rats
Current Psychopharmacology Meet Our Associate Editor
Current Cardiology Reviews Incidence and Risk Factors for Tenofovir-Associated Renal Function Decline Among Thai HIV-Infected Patients with Low-Body Weight
Current HIV Research The Nutrigenetics and Pharmacogenetics of Vitamin D Pathways
Current Pharmacogenomics and Personalized Medicine Transcriptome-wide Association Study Identifies Genetically Dysregulated Genes in Diabetic Neuropathy
Combinatorial Chemistry & High Throughput Screening Virtual Screening, Docking, Synthesis and Bioactivity Evaluation of Thiazolidinediones as Potential PPARγ Partial Agonists for Preparation of Antidiabetic Agents
Letters in Drug Design & Discovery Recent Medicinal Chemistry Studies for Multitarget Agents-Part II
Current Drug Targets Clinical Predictors of Diabetic Retinopathy Progression; A Systematic Review
Current Diabetes Reviews Practical Application of Antidiabetic Efficacy of <i>Lycium barbarum</i> Polysaccharide in Patients with Type 2 Diabetes
Medicinal Chemistry The Clinical Pathway for Hypertensive Patient of Local Health Unit, Hospitals and General Practitioners, the Milan Experience
Reviews on Recent Clinical Trials High-Density Lipoprotein-Raising Strategies: Update 2010
Current Pharmaceutical Design Exploring Shared Pathogenesis of Alzheimer’s Disease and Type 2 Diabetes Mellitus via Co-expression Networks Analysis
Current Alzheimer Research Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome
Current Vascular Pharmacology Vitamin, Mineral, and Drug Absorption Following Bariatric Surgery
Current Drug Metabolism Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future
Current Topics in Medicinal Chemistry Advances in the Generation of Functional β-cells from Induced Pluripotent Stem Cells As a Cure for Diabetes Mellitus
Current Drug Targets Effects of Melatonin on Peripheral Nerve Regeneration
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Vascular, Oxidative, and Synaptosomal Abnormalities During Aging and the Progression of Type 2 Diabetes
Current Neurovascular Research Nanowired Drug Delivery Across the Blood-Brain Barrier in Central Nervous System Injury and Repair
CNS & Neurological Disorders - Drug Targets Coronavirus Disease 2019 (COVID-19) and Pregnancy: A Narrative Review
Current Pediatric Reviews